Natera Guardant Health Sues Natera for False Advertising, 'Misleading' Oncologists About MRD Tests Guardant has asked the court to recover damages and to prevent Natera from further disseminating "deceptive" advertising regarding their competing assays. Invitae Sues Natera Alleging Infringement of Patent on DNA Sequencing Assembly Technique Invitae believes its '799 patent improves upon prior art and wants a US District Court to find that Natera is infringing its IP with its Signatera test. Natera Q1 Revenues Grow 62 Percent The company reported $152.3 million in total revenues for the quarter and said the number of tests it processed rose 48 percent from the prior-year quarter. Personalis Q1 Revenues Grow 9 Percent The firm tallied $20.9 million in revenues compared to $19.2 million a year ago, edging analysts' consensus estimate of $20.4 million. Medicare Administrative Contractor Palmetto Finalizes Coverage of Molecular Testing for Organ Transplant Rejection Under the policy, covered tests must provide information about active rejection status or cellular or antibody-mediated rejection status. Feb 26, 2021 Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year Premium Feb 26, 2021 Personalis to Broaden Liquid Biopsy Footprint With Minimal Residual Disease Testing Premium Feb 25, 2021 Natera Revenues Grow 35 Percent in Q4 Feb 17, 2021 Natera, Personalis Team up for Cancer Treatment Monitoring, MRD Testing Jan 27, 2021 Heart Transplant Cell-Free DNA Test Enables Earlier Detection of Acute Rejection Than Biopsy Premium Jan 20, 2021 Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents Jan 13, 2021 At JPM, Natera CEO Lays Out Growth Potential for NIPT, Transplant, Cancer Testing Dec 23, 2020 In Brief This Week: Natera, Sync for Genes, Castle Biosciences, BioMérieux, PathogenDx, More Dec 4, 2020 Breast Cancer Trial Data Supports Neoadjuvant Use of Natera Liquid Biopsy Premium Dec 3, 2020 Aetna Updates Noninvasive Prenatal Testing Coverage Policy to Include All Pregnancies Dec 2, 2020 Judge Denies Natera Motion to Invalidate CareDx, Stanford Patents Dec 1, 2020 UnitedHealthcare to Cover NIPT for Average-Risk Pregnancies Nov 20, 2020 People in the News: New Appointments at Natera, Quanterix, Sophia Genetics, More Nov 6, 2020 Natera Expects Further Growth in NIPT as it Expands Use Cases for Cancer, Transplant Tests Premium Nov 5, 2020 Natera Q3 Revenues Up 26 Percent on Increased Testing Volumes Nov 3, 2020 Natera Aims to Improve Prospera Kidney Test After Findings Reveal Cell-Free DNA Changes in Infection Premium Oct 29, 2020 Humana Broadens Coverage of NIPT for Average Risk Pregnancies Oct 8, 2020 Centene Expands Coverage of Natera NIPT to All Pregnant Women Oct 7, 2020 Natera Sues Genosity for Patent Infringement Relating to ArcherDx Products Oct 5, 2020 Federal Court Rejects ArcherDx Motion Against Natera in Patent Infringement Lawsuit Load More Breaking News Cytosine Base Editor Enables Genome-Wide Genetic Function Screening G42 Healthcare, Seegene to Offer Mobile Molecular Diagnostic Labs in Middle East, North Africa JP Morgan, Cowen Initiate Coverage of Singular Genomics Systems Top Five Articles on GenomeWeb Last Week: Danaher, Becton Dickinson, 23andMe, and More Berry Oncology, Alibaba Health Partner to Offer Early Cancer Screening, Health Services Roche Receives FDA EUA for PCR-Based, Point-of-Care SARS-CoV-2 Test The Scan Renewed Gain-of-Function Worries The New York Times writes that the pandemic is renewing concerns about gain-of-function research. Who's Getting the Patents? A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports. Other Uses CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2. PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.